Transdermal sumatriptan closer to marketing
This article was originally published in Scrip
The private US company NuPathe plans to submit a US NDA next year for its novel iontophoretic sumatriptan patch, Zelrix. NuPathe expects Zelrix to be the first transdermal patch to be marketed for migraine.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.